SCHEMBL21611965

SCHEMBL21611965

Nc1cc(SCc2nc3cc(Oc4cccc(F)c4)ccc3[nH]2)nc(C(F)(F)F)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRIN1 Q05586 2/20 0.35
▸ GRIN2B Q13224 2/20 0.35
▸ RAB9A P51151 5/20 0.34
▸ NPC1 O15118 4/20 0.34
▸ LMNA P02545 3/20 0.34
▸ POLB P06746 2/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ MAOA P21397 1/20 0.33
▸ MAOB P27338 1/20 0.33
▸ ABCB1 P08183 2/20 0.32
▸ CYP1A2 P05177 2/20 0.32
▸ CYP3A4 P08684 2/20 0.32
▸ CYP2D6 P10635 2/20 0.32
▸ CYP2C9 P11712 2/20 0.32
▸ CYP2C19 P33261 2/20 0.32
▸ SMN1; SMN2 Q16637 2/20 0.32
▸ MAPT P10636 4/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21614659 0.92 GRIN1 (0.34) GRIN1GRIN2BRAB9ANPC1LMNA
SCHEMBL21611990 0.92 GRIN1 (0.43) GRIN1GRIN2BRAB9ANPC1LMNA
SCHEMBL21614675 0.90 CYP1A2 (0.42) GRIN1GRIN2BRAB9ANPC1LMNA
SCHEMBL21612028 0.87 LMNA (0.35) GRIN1GRIN2BRAB9ANPC1LMNA
SCHEMBL26260528 0.83 ABCB1 (0.42) RAB9ANPC1LMNAABCB1SMN1; SMN2
SCHEMBL21612025 0.80 LMNA (0.41) GRIN1GRIN2BRAB9ANPC1LMNA
SCHEMBL21612011 0.79 NPC1 (0.42) RAB9ANPC1LMNAPOLBMAPK1
SCHEMBL21611966 0.79 GRIN1 (0.41) GRIN1GRIN2BRAB9ANPC1LMNA
SCHEMBL24027392 0.77 NPC1 (0.43) GRIN1GRIN2BRAB9ANPC1LMNA
SCHEMBL24027538 0.77 CYP1A2 (0.45) GRIN1GRIN2BRAB9ANPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
EP-3818045-A1 PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-05-12 — — EP disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353606-A1 PqsR INVERSE AGONISTS QRFPR, P2RY11, QARS1 GRIN1 1447/4885GRIN2B 1208/4885RAB9A 722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback